These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Chu MC, Carmina E, Wang J, Lobo RA. Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965 [Abstract] [Full Text] [Related]
25. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA, Shin SY, Yoon BK, Choi D. Gynecol Endocrinol; 2007 Dec; 23(8):461-7. PubMed ID: 17852414 [Abstract] [Full Text] [Related]
26. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome. van der Westhuizen S, van der Spuy ZM. Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098 [Abstract] [Full Text] [Related]
27. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. J Clin Endocrinol Metab; 1998 May; 83(5):1730-5. PubMed ID: 9589683 [Abstract] [Full Text] [Related]
28. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R. J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050 [Abstract] [Full Text] [Related]
29. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Androulakis II, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, Diamanti-Kandarakis E. Clin Endocrinol (Oxf); 2014 Sep; 81(3):426-31. PubMed ID: 24601936 [Abstract] [Full Text] [Related]
30. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D. Hum Reprod; 2017 Aug 01; 32(8):1716-1722. PubMed ID: 28854589 [Abstract] [Full Text] [Related]
31. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. J Clin Endocrinol Metab; 2006 Oct 01; 91(10):3922-7. PubMed ID: 16849400 [Abstract] [Full Text] [Related]
32. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome. Yang Z, Zhou W, Zhou C, Zhou Y, Liu X, Ding G, Hu Y, Pan J, Sheng J, Jin L, Huang H. J Steroid Biochem Mol Biol; 2021 Feb 01; 206():105806. PubMed ID: 33340681 [Abstract] [Full Text] [Related]
33. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Pierre A, Peigné M, Grynberg M, Arouche N, Taieb J, Hesters L, Gonzalès J, Picard JY, Dewailly D, Fanchin R, Catteau-Jonard S, di Clemente N. Hum Reprod; 2013 Mar 01; 28(3):762-9. PubMed ID: 23321213 [Abstract] [Full Text] [Related]
34. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J. Arch Gynecol Obstet; 2013 Mar 01; 287(3):525-31. PubMed ID: 23108387 [Abstract] [Full Text] [Related]
35. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age]. Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E. Akush Ginekol (Sofiia); 2013 Mar 01; 52 Suppl 1():16-23. PubMed ID: 24294740 [Abstract] [Full Text] [Related]
36. [Exploration of the classification of polycystic ovarian syndrome]. Lin JF, Li X, Zhu MW. Zhonghua Fu Chan Ke Za Zhi; 2006 Oct 01; 41(10):684-8. PubMed ID: 17199924 [Abstract] [Full Text] [Related]
37. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA. J Clin Endocrinol Metab; 2000 Mar 01; 85(3):995-1000. PubMed ID: 10720029 [Abstract] [Full Text] [Related]
38. Effect of DHT-Induced Hyperandrogenism on the Pro-Inflammatory Cytokines in a Rat Model of Polycystic Ovary Morphology. Krishnan A, Muthusami S, Periyasamy L, Stanley JA, Gopalakrishnan V, Ramachandran I. Medicina (Kaunas); 2020 Feb 27; 56(3):. PubMed ID: 32120970 [Abstract] [Full Text] [Related]
39. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Hum Reprod; 2011 Nov 27; 26(11):3123-9. PubMed ID: 21926054 [Abstract] [Full Text] [Related]
40. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. J Clin Endocrinol Metab; 2000 Aug 27; 85(8):2767-74. PubMed ID: 10946879 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]